Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Mersana Therapeutics Inc
MRSN | US
2.10
USD0
0%
MRSN | US
About Mersana Therapeutics Inc
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
21/10/2024
Close
2.10
Open
2.10
High
2.14
Low
2.08
Mersana Therapeutics Inc. a clinical stage biopharmaceutical company develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660 a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056 an immunosynthen ADC. It has a research and development collaborations with Janssen Biotech Inc. and Merck KGaA as well as collaboration agreement with Asana BioSciences LLC for the development of ADC product candidates. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics Inc. in November 2005. Mersana Therapeutics Inc. was incorporated in 2001 and is headquartered in Cambridge Massachusetts.
View LessMRSN | US
Risk
76.1
Sharpe
0.35
Luna's Score
37/100
Recommendation
Sell
Luna says (MRSN | US)
What's Working
Low Debt to Asset (< 0.2)
What's not Working
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Market Beta (> 0.8)
High Debt to Equity (> 0.75)
Rich in Valuation (Price to Book > 8)
Weak Operating Margin (< 10%)
Declining Revenue (< 0%)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
10 days
59.0%1 month
76.1%3 months
103.3%6 months
93.9%Returns
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
30.57
Debt to equity
3.83
Debt to assets
0.18
Ent. to EBITDA
-2.20
Ent. to rev.
4.25
PEG
-
Other Fundamentals
EBITDA
-101.41M
MarketCap
257.62M
MarketCap(USD)
257.62M
Div. yield
-
Op. margin
-1.11K
Erngs. growth
-
Rev. growth
-78.50
Ret. on equity
-213.33
Short ratio
9.65
Short perc.
10.22
Market Sentiment (SMA and Price signals)
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
SMAs: Stock Price Trends
Range10D
0.34
Range1M
0.41
Range3M
1.05
Volumes: Market Activity
Rel. volume
0.38
Price X volume
619.96K
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -2.20 | - | Cheaper |
| Ent. to Revenue | 4.25 | - | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 30.57 | 15.55 | Expensive |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 103.31 | - | Riskier |
| Debt to Equity | 3.83 | -1.23 | Expensive |
| Debt to Assets | 0.18 | 0.25 | Cheaper |
| Market Cap | 257.62M | - | Emerging |
